Cargando…
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
PURPOSE: This article introduces the new 5-level EQ-5D (EQ-5D-5L) health status measure. METHODS: EQ-5D currently measures health using three levels of severity in five dimensions. A EuroQol Group task force was established to find ways of improving the instrument’s sensitivity and reducing ceiling...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3220807/ https://www.ncbi.nlm.nih.gov/pubmed/21479777 http://dx.doi.org/10.1007/s11136-011-9903-x |
_version_ | 1782216998071042048 |
---|---|
author | Herdman, M. Gudex, C. Lloyd, A. Janssen, MF. Kind, P. Parkin, D. Bonsel, G. Badia, X. |
author_facet | Herdman, M. Gudex, C. Lloyd, A. Janssen, MF. Kind, P. Parkin, D. Bonsel, G. Badia, X. |
author_sort | Herdman, M. |
collection | PubMed |
description | PURPOSE: This article introduces the new 5-level EQ-5D (EQ-5D-5L) health status measure. METHODS: EQ-5D currently measures health using three levels of severity in five dimensions. A EuroQol Group task force was established to find ways of improving the instrument’s sensitivity and reducing ceiling effects by increasing the number of severity levels. The study was performed in the United Kingdom and Spain. Severity labels for 5 levels in each dimension were identified using response scaling. Focus groups were used to investigate the face and content validity of the new versions, including hypothetical health states generated from those versions. RESULTS: Selecting labels at approximately the 25th, 50th, and 75th centiles produced two alternative 5-level versions. Focus group work showed a slight preference for the wording ‘slight-moderate-severe’ problems, with anchors of ‘no problems’ and ‘unable to do’ in the EQ-5D functional dimensions. Similar wording was used in the Pain/Discomfort and Anxiety/Depression dimensions. Hypothetical health states were well understood though participants stressed the need for the internal coherence of health states. CONCLUSIONS: A 5-level version of the EQ-5D has been developed by the EuroQol Group. Further testing is required to determine whether the new version improves sensitivity and reduces ceiling effects. |
format | Online Article Text |
id | pubmed-3220807 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-32208072011-12-09 Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Herdman, M. Gudex, C. Lloyd, A. Janssen, MF. Kind, P. Parkin, D. Bonsel, G. Badia, X. Qual Life Res Article PURPOSE: This article introduces the new 5-level EQ-5D (EQ-5D-5L) health status measure. METHODS: EQ-5D currently measures health using three levels of severity in five dimensions. A EuroQol Group task force was established to find ways of improving the instrument’s sensitivity and reducing ceiling effects by increasing the number of severity levels. The study was performed in the United Kingdom and Spain. Severity labels for 5 levels in each dimension were identified using response scaling. Focus groups were used to investigate the face and content validity of the new versions, including hypothetical health states generated from those versions. RESULTS: Selecting labels at approximately the 25th, 50th, and 75th centiles produced two alternative 5-level versions. Focus group work showed a slight preference for the wording ‘slight-moderate-severe’ problems, with anchors of ‘no problems’ and ‘unable to do’ in the EQ-5D functional dimensions. Similar wording was used in the Pain/Discomfort and Anxiety/Depression dimensions. Hypothetical health states were well understood though participants stressed the need for the internal coherence of health states. CONCLUSIONS: A 5-level version of the EQ-5D has been developed by the EuroQol Group. Further testing is required to determine whether the new version improves sensitivity and reduces ceiling effects. Springer Netherlands 2011-04-09 2011 /pmc/articles/PMC3220807/ /pubmed/21479777 http://dx.doi.org/10.1007/s11136-011-9903-x Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Article Herdman, M. Gudex, C. Lloyd, A. Janssen, MF. Kind, P. Parkin, D. Bonsel, G. Badia, X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) |
title | Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) |
title_full | Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) |
title_fullStr | Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) |
title_full_unstemmed | Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) |
title_short | Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) |
title_sort | development and preliminary testing of the new five-level version of eq-5d (eq-5d-5l) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3220807/ https://www.ncbi.nlm.nih.gov/pubmed/21479777 http://dx.doi.org/10.1007/s11136-011-9903-x |
work_keys_str_mv | AT herdmanm developmentandpreliminarytestingofthenewfivelevelversionofeq5deq5d5l AT gudexc developmentandpreliminarytestingofthenewfivelevelversionofeq5deq5d5l AT lloyda developmentandpreliminarytestingofthenewfivelevelversionofeq5deq5d5l AT janssenmf developmentandpreliminarytestingofthenewfivelevelversionofeq5deq5d5l AT kindp developmentandpreliminarytestingofthenewfivelevelversionofeq5deq5d5l AT parkind developmentandpreliminarytestingofthenewfivelevelversionofeq5deq5d5l AT bonselg developmentandpreliminarytestingofthenewfivelevelversionofeq5deq5d5l AT badiax developmentandpreliminarytestingofthenewfivelevelversionofeq5deq5d5l |